State of Artemisinin and Partner Drug Susceptibility in Plasmodium falciparum Clinical Isolates from Colombia

ABSTRACT: Delayed parasite clearance time observed in Southeast Asia provided the first evidence of Plasmodium falciparum resistance to artemisinins. The ex vivo ring-stage survival assay (RSA) mimics parasite exposure to pharmacologically relevant artemisinin concentrations. Mutations in the C-term...

Full description

Autores:
Montenegro Cadena, Lidia Madeline
de Las Salas Calderón, Briegel
Tobón Castaño, Alberto
Lopera Mesa, Tatiana María
Fairhurst, Rick M.
Neal, Aaron T.
Tipo de recurso:
Article of investigation
Fecha de publicación:
2021
Institución:
Universidad de Antioquia
Repositorio:
Repositorio UdeA
Idioma:
eng
OAI Identifier:
oai:bibliotecadigital.udea.edu.co:10495/42051
Acceso en línea:
https://hdl.handle.net/10495/42051
Palabra clave:
Antimaláricos
Antimalarials
Resistencia a Medicamentos
Drug Resistance
Malaria Falciparum
Malaria, Falciparum
Plasmodium falciparum
Proteínas Asociadas a Resistencia a Múltiples Medicamentos
Multidrug Resistance-Associated Proteins
Reacción en Cadena de la Polimerasa
Polymerase Chain Reaction
Colombia - epidemiología
Colombia - epidemiology
https://id.nlm.nih.gov/mesh/D000962
https://id.nlm.nih.gov/mesh/D004351
https://id.nlm.nih.gov/mesh/D016778
https://id.nlm.nih.gov/mesh/D010963
https://id.nlm.nih.gov/mesh/D027425
https://id.nlm.nih.gov/mesh/D016133
https://id.nlm.nih.gov/mesh/D003105
Rights
openAccess
License
https://creativecommons.org/licenses/by/4.0/
id UDEA2_9cb33206780c650d33980f1837efcb18
oai_identifier_str oai:bibliotecadigital.udea.edu.co:10495/42051
network_acronym_str UDEA2
network_name_str Repositorio UdeA
repository_id_str
dc.title.spa.fl_str_mv State of Artemisinin and Partner Drug Susceptibility in Plasmodium falciparum Clinical Isolates from Colombia
title State of Artemisinin and Partner Drug Susceptibility in Plasmodium falciparum Clinical Isolates from Colombia
spellingShingle State of Artemisinin and Partner Drug Susceptibility in Plasmodium falciparum Clinical Isolates from Colombia
Antimaláricos
Antimalarials
Resistencia a Medicamentos
Drug Resistance
Malaria Falciparum
Malaria, Falciparum
Plasmodium falciparum
Proteínas Asociadas a Resistencia a Múltiples Medicamentos
Multidrug Resistance-Associated Proteins
Reacción en Cadena de la Polimerasa
Polymerase Chain Reaction
Colombia - epidemiología
Colombia - epidemiology
https://id.nlm.nih.gov/mesh/D000962
https://id.nlm.nih.gov/mesh/D004351
https://id.nlm.nih.gov/mesh/D016778
https://id.nlm.nih.gov/mesh/D010963
https://id.nlm.nih.gov/mesh/D027425
https://id.nlm.nih.gov/mesh/D016133
https://id.nlm.nih.gov/mesh/D003105
title_short State of Artemisinin and Partner Drug Susceptibility in Plasmodium falciparum Clinical Isolates from Colombia
title_full State of Artemisinin and Partner Drug Susceptibility in Plasmodium falciparum Clinical Isolates from Colombia
title_fullStr State of Artemisinin and Partner Drug Susceptibility in Plasmodium falciparum Clinical Isolates from Colombia
title_full_unstemmed State of Artemisinin and Partner Drug Susceptibility in Plasmodium falciparum Clinical Isolates from Colombia
title_sort State of Artemisinin and Partner Drug Susceptibility in Plasmodium falciparum Clinical Isolates from Colombia
dc.creator.fl_str_mv Montenegro Cadena, Lidia Madeline
de Las Salas Calderón, Briegel
Tobón Castaño, Alberto
Lopera Mesa, Tatiana María
Fairhurst, Rick M.
Neal, Aaron T.
dc.contributor.author.none.fl_str_mv Montenegro Cadena, Lidia Madeline
de Las Salas Calderón, Briegel
Tobón Castaño, Alberto
Lopera Mesa, Tatiana María
Fairhurst, Rick M.
Neal, Aaron T.
dc.contributor.researchgroup.spa.fl_str_mv Grupo Malaria
dc.subject.decs.none.fl_str_mv Antimaláricos
Antimalarials
Resistencia a Medicamentos
Drug Resistance
Malaria Falciparum
Malaria, Falciparum
Plasmodium falciparum
Proteínas Asociadas a Resistencia a Múltiples Medicamentos
Multidrug Resistance-Associated Proteins
Reacción en Cadena de la Polimerasa
Polymerase Chain Reaction
Colombia - epidemiología
Colombia - epidemiology
topic Antimaláricos
Antimalarials
Resistencia a Medicamentos
Drug Resistance
Malaria Falciparum
Malaria, Falciparum
Plasmodium falciparum
Proteínas Asociadas a Resistencia a Múltiples Medicamentos
Multidrug Resistance-Associated Proteins
Reacción en Cadena de la Polimerasa
Polymerase Chain Reaction
Colombia - epidemiología
Colombia - epidemiology
https://id.nlm.nih.gov/mesh/D000962
https://id.nlm.nih.gov/mesh/D004351
https://id.nlm.nih.gov/mesh/D016778
https://id.nlm.nih.gov/mesh/D010963
https://id.nlm.nih.gov/mesh/D027425
https://id.nlm.nih.gov/mesh/D016133
https://id.nlm.nih.gov/mesh/D003105
dc.subject.meshuri.none.fl_str_mv https://id.nlm.nih.gov/mesh/D000962
https://id.nlm.nih.gov/mesh/D004351
https://id.nlm.nih.gov/mesh/D016778
https://id.nlm.nih.gov/mesh/D010963
https://id.nlm.nih.gov/mesh/D027425
https://id.nlm.nih.gov/mesh/D016133
https://id.nlm.nih.gov/mesh/D003105
description ABSTRACT: Delayed parasite clearance time observed in Southeast Asia provided the first evidence of Plasmodium falciparum resistance to artemisinins. The ex vivo ring-stage survival assay (RSA) mimics parasite exposure to pharmacologically relevant artemisinin concentrations. Mutations in the C-terminal propeller domain of the putative kelch protein Pf3D7_1343700 (K13) are associated with artemisinin resistance. Variations in the pfmdr1 gene are associated with reduced susceptibility to the artemisinin partner drugs mefloquine (MQ) and lumefantrine (LF). To clarify the unknown landscape of artemisinin resistance in Colombia, 71 patients with uncomplicated P. falciparum malaria were enrolled in a non-randomized observational study in three endemic localities in 2014-2015. Each patient's parasite isolate was assessed for ex vivo RSA, K13-propeller mutations, pfmdr1 copy number, and pfmdr1 mutations at codons 86, 184, 1034, 1042, and 1246, associated with reduced susceptibility, and 50% inhibitory concentration (IC50) for other antimalarial drugs. Ex vivo RSAs were successful in 56% (40/71) of samples, and nine isolates showed survival rates > 1%. All isolates had wild-type K13-propeller sequences. All isolates harbored either of two pfmdr1 haplotypes, NFSDD (79.3%) and NFSDY (20.7%), and 7.1% of isolates had > 1 pfmdr1 gene. In vitro IC50 assays showed that variable proportions of isolates had decreased susceptibility to chloroquine (52.4%, > 100 nM), amodiaquine (31.2%, > 30 nM), MQ (34.3%, > 30 nM), and LF (3.2%, > 10 nM). In this study, we report ex vivo RSA and K13 data on P. falciparum isolates from Colombia. The identification of isolates with increased ex vivo RSA rates in the absence of K13-propeller mutations and no positivity at day three requires further investigation.
publishDate 2021
dc.date.issued.none.fl_str_mv 2021
dc.date.accessioned.none.fl_str_mv 2024-09-12T01:14:53Z
dc.date.available.none.fl_str_mv 2024-09-12T01:14:53Z
dc.type.spa.fl_str_mv Artículo de investigación
dc.type.coar.spa.fl_str_mv http://purl.org/coar/resource_type/c_2df8fbb1
dc.type.redcol.spa.fl_str_mv https://purl.org/redcol/resource_type/ART
dc.type.coarversion.spa.fl_str_mv http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.driver.spa.fl_str_mv info:eu-repo/semantics/article
dc.type.version.spa.fl_str_mv info:eu-repo/semantics/publishedVersion
format http://purl.org/coar/resource_type/c_2df8fbb1
status_str publishedVersion
dc.identifier.citation.spa.fl_str_mv Montenegro LM, de Las Salas B, Neal AT, Tobon-Castaño A, Fairhurst RM, Lopera-Mesa TM. State of Artemisinin and Partner Drug Susceptibility in Plasmodium falciparum Clinical Isolates from Colombia. Am J Trop Med Hyg. 2021 Jan;104(1):263-270. doi: 10.4269/ajtmh.20-0148.
dc.identifier.issn.none.fl_str_mv 0002-9637
dc.identifier.uri.none.fl_str_mv https://hdl.handle.net/10495/42051
dc.identifier.doi.none.fl_str_mv 10.4269/ajtmh.20-0148
dc.identifier.eissn.none.fl_str_mv 1476-1645
identifier_str_mv Montenegro LM, de Las Salas B, Neal AT, Tobon-Castaño A, Fairhurst RM, Lopera-Mesa TM. State of Artemisinin and Partner Drug Susceptibility in Plasmodium falciparum Clinical Isolates from Colombia. Am J Trop Med Hyg. 2021 Jan;104(1):263-270. doi: 10.4269/ajtmh.20-0148.
0002-9637
10.4269/ajtmh.20-0148
1476-1645
url https://hdl.handle.net/10495/42051
dc.language.iso.spa.fl_str_mv eng
language eng
dc.relation.ispartofjournalabbrev.spa.fl_str_mv Am. J. Trop. Med. Hyg.
dc.relation.citationendpage.spa.fl_str_mv 270
dc.relation.citationissue.spa.fl_str_mv 1
dc.relation.citationstartpage.spa.fl_str_mv 263
dc.relation.citationvolume.spa.fl_str_mv 104
dc.relation.ispartofjournal.spa.fl_str_mv American Journal of Tropical Medicine and Hygiene
dc.rights.uri.spa.fl_str_mv https://creativecommons.org/licenses/by/4.0/
dc.rights.uri.*.fl_str_mv http://creativecommons.org/licenses/by/2.5/co/
dc.rights.accessrights.spa.fl_str_mv info:eu-repo/semantics/openAccess
dc.rights.coar.spa.fl_str_mv http://purl.org/coar/access_right/c_abf2
rights_invalid_str_mv https://creativecommons.org/licenses/by/4.0/
http://creativecommons.org/licenses/by/2.5/co/
http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv openAccess
dc.format.extent.spa.fl_str_mv 8 páginas
dc.format.mimetype.spa.fl_str_mv application/pdf
dc.publisher.spa.fl_str_mv American Society of Tropical Medicine and Hygiene
dc.publisher.place.spa.fl_str_mv Baltimore, Estados Unidos
institution Universidad de Antioquia
bitstream.url.fl_str_mv https://bibliotecadigital.udea.edu.co/bitstreams/59e3f373-7436-45dd-94b7-a02c39231d0c/download
https://bibliotecadigital.udea.edu.co/bitstreams/c17ac891-f89b-4088-bbd4-d6fad92896d6/download
https://bibliotecadigital.udea.edu.co/bitstreams/f1bd7946-5837-459a-92b9-8e362bfecc82/download
https://bibliotecadigital.udea.edu.co/bitstreams/5a81a233-091b-4c0a-83d9-17dc9f5c0a54/download
https://bibliotecadigital.udea.edu.co/bitstreams/00e77eab-bbdf-4474-a21b-a1b9e7920041/download
bitstream.checksum.fl_str_mv 1413a569f632cc510c84e47071d453fc
8a4605be74aa9ea9d79846c1fba20a33
1646d1f6b96dbbbc38035efc9239ac9c
7cc3e9f04b2402b2fc92fd613b0e46d4
b15ec8c112a3bea31eda973797bdb025
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
MD5
repository.name.fl_str_mv Repositorio Institucional de la Universidad de Antioquia
repository.mail.fl_str_mv aplicacionbibliotecadigitalbiblioteca@udea.edu.co
_version_ 1851052273020436480
spelling Montenegro Cadena, Lidia Madelinede Las Salas Calderón, BriegelTobón Castaño, AlbertoLopera Mesa, Tatiana MaríaFairhurst, Rick M.Neal, Aaron T.Grupo Malaria2024-09-12T01:14:53Z2024-09-12T01:14:53Z2021Montenegro LM, de Las Salas B, Neal AT, Tobon-Castaño A, Fairhurst RM, Lopera-Mesa TM. State of Artemisinin and Partner Drug Susceptibility in Plasmodium falciparum Clinical Isolates from Colombia. Am J Trop Med Hyg. 2021 Jan;104(1):263-270. doi: 10.4269/ajtmh.20-0148.0002-9637https://hdl.handle.net/10495/4205110.4269/ajtmh.20-01481476-1645ABSTRACT: Delayed parasite clearance time observed in Southeast Asia provided the first evidence of Plasmodium falciparum resistance to artemisinins. The ex vivo ring-stage survival assay (RSA) mimics parasite exposure to pharmacologically relevant artemisinin concentrations. Mutations in the C-terminal propeller domain of the putative kelch protein Pf3D7_1343700 (K13) are associated with artemisinin resistance. Variations in the pfmdr1 gene are associated with reduced susceptibility to the artemisinin partner drugs mefloquine (MQ) and lumefantrine (LF). To clarify the unknown landscape of artemisinin resistance in Colombia, 71 patients with uncomplicated P. falciparum malaria were enrolled in a non-randomized observational study in three endemic localities in 2014-2015. Each patient's parasite isolate was assessed for ex vivo RSA, K13-propeller mutations, pfmdr1 copy number, and pfmdr1 mutations at codons 86, 184, 1034, 1042, and 1246, associated with reduced susceptibility, and 50% inhibitory concentration (IC50) for other antimalarial drugs. Ex vivo RSAs were successful in 56% (40/71) of samples, and nine isolates showed survival rates > 1%. All isolates had wild-type K13-propeller sequences. All isolates harbored either of two pfmdr1 haplotypes, NFSDD (79.3%) and NFSDY (20.7%), and 7.1% of isolates had > 1 pfmdr1 gene. In vitro IC50 assays showed that variable proportions of isolates had decreased susceptibility to chloroquine (52.4%, > 100 nM), amodiaquine (31.2%, > 30 nM), MQ (34.3%, > 30 nM), and LF (3.2%, > 10 nM). In this study, we report ex vivo RSA and K13 data on P. falciparum isolates from Colombia. The identification of isolates with increased ex vivo RSA rates in the absence of K13-propeller mutations and no positivity at day three requires further investigation.COL00075248 páginasapplication/pdfengAmerican Society of Tropical Medicine and HygieneBaltimore, Estados Unidoshttps://creativecommons.org/licenses/by/4.0/http://creativecommons.org/licenses/by/2.5/co/info:eu-repo/semantics/openAccesshttp://purl.org/coar/access_right/c_abf2State of Artemisinin and Partner Drug Susceptibility in Plasmodium falciparum Clinical Isolates from ColombiaArtículo de investigaciónhttp://purl.org/coar/resource_type/c_2df8fbb1https://purl.org/redcol/resource_type/ARThttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionAntimaláricosAntimalarialsResistencia a MedicamentosDrug ResistanceMalaria FalciparumMalaria, FalciparumPlasmodium falciparumProteínas Asociadas a Resistencia a Múltiples MedicamentosMultidrug Resistance-Associated ProteinsReacción en Cadena de la PolimerasaPolymerase Chain ReactionColombia - epidemiologíaColombia - epidemiologyhttps://id.nlm.nih.gov/mesh/D000962https://id.nlm.nih.gov/mesh/D004351https://id.nlm.nih.gov/mesh/D016778https://id.nlm.nih.gov/mesh/D010963https://id.nlm.nih.gov/mesh/D027425https://id.nlm.nih.gov/mesh/D016133https://id.nlm.nih.gov/mesh/D003105Am. J. Trop. Med. Hyg.2701263104American Journal of Tropical Medicine and HygienePublicationORIGINALLoperaTatiana_2021_Durg_Susceptibility_Plasmodium.pdfLoperaTatiana_2021_Durg_Susceptibility_Plasmodium.pdfArtículo de investigaciónapplication/pdf356185https://bibliotecadigital.udea.edu.co/bitstreams/59e3f373-7436-45dd-94b7-a02c39231d0c/download1413a569f632cc510c84e47071d453fcMD51trueAnonymousREADLICENSElicense.txtlicense.txttext/plain; charset=utf-81748https://bibliotecadigital.udea.edu.co/bitstreams/c17ac891-f89b-4088-bbd4-d6fad92896d6/download8a4605be74aa9ea9d79846c1fba20a33MD53falseAnonymousREADCC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-8927https://bibliotecadigital.udea.edu.co/bitstreams/f1bd7946-5837-459a-92b9-8e362bfecc82/download1646d1f6b96dbbbc38035efc9239ac9cMD52falseAnonymousREADTEXTLoperaTatiana_2021_Durg_Susceptibility_Plasmodium.pdf.txtLoperaTatiana_2021_Durg_Susceptibility_Plasmodium.pdf.txtExtracted texttext/plain49030https://bibliotecadigital.udea.edu.co/bitstreams/5a81a233-091b-4c0a-83d9-17dc9f5c0a54/download7cc3e9f04b2402b2fc92fd613b0e46d4MD54falseAnonymousREADTHUMBNAILLoperaTatiana_2021_Durg_Susceptibility_Plasmodium.pdf.jpgLoperaTatiana_2021_Durg_Susceptibility_Plasmodium.pdf.jpgGenerated Thumbnailimage/jpeg17949https://bibliotecadigital.udea.edu.co/bitstreams/00e77eab-bbdf-4474-a21b-a1b9e7920041/downloadb15ec8c112a3bea31eda973797bdb025MD55falseAnonymousREAD10495/42051oai:bibliotecadigital.udea.edu.co:10495/420512025-03-26 19:41:40.885https://creativecommons.org/licenses/by/4.0/open.accesshttps://bibliotecadigital.udea.edu.coRepositorio Institucional de la Universidad de Antioquiaaplicacionbibliotecadigitalbiblioteca@udea.edu.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